Fundraising Fox

Aura Biosciences

NASDAQ: AURA

Cambridge, US · Founded 2009 · Delaware corporation · 11 known investors

aurabiosciences.com ↗

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.

BiotechHealthtechMedical Devices

Founders & leadership

Aura Biosciences was founded in 2009 by Elisabet de los Pinos, Ph.D. and Elisabet de los Pinos.

ED
Elisabet de los Pinos, Ph.D.Co-founder
ED
Elisabet de los PinosinFounder & CEO
MW
Michael WyzgaExecutive
DP
Dale Pfost, Ph.D.Named on SEC filing
AE
Alan E. Walts, Ph.D.Named on SEC filing
LG
Lewis GeffenNamed on SEC filing
PW
Peter WirthNamed on SEC filing
JB
Jose Baselga, Ph.d.Named on SEC filing
IR
Israel RuizNamed on SEC filing
AW
Alan WaltsNamed on SEC filing
SG
Salvador Garcia-AtanceNamed on SEC filing
ED
Elisabet de los Pinos, Ph.d.President and Treasurer

Investors · 11

Advent Life SciencesLondon
Chiesi VenturesBoston · $5M
Droia VenturesLeuven · $540K
Foresite CapitalLarkspur
Jazzya InvestmentsAlcobendasvia Martin Varsavsky · inferred
MedicxiLondon
Myelin VCMontevideo · $250K – $1Mvia Matias Nisenson · inferred
OrbiMedNew York · $1M – $75M
venBio PartnersSan Francisco
Ysios CapitalBarcelona · $5.4M – $21.6M
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred

Reported raises · per SEC filings

Form D private placements

$190.6M disclosed across 8 of 9 rounds · 2013–2026

▶$80.5MraisedApr 2021 · 41 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Karan TakharDirector
  • Julie FederExecutive Officer
  • Raj Parekh, Ph.D.Director
  • Elisabet de los Pinos, Ph.D.Executive Officer, Director
  • Giovanni Mariggi, Ph.D.Director
  • David JohnsonDirector
Offering amount
$80.5M
Amount sold
$80.5M
First sale
Mar 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedJul 2020 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christian SchetterDirector
  • Elisabet de los Pinos, Ph.D.Executive Officer, Director
  • Raj Parekh, Ph.D.Director
  • Giovanni Mariggi, Ph.D.Director
  • Julie FederExecutive Officer
  • George Golumbeski, Ph.D.Director
  • Art PappasDirector
  • Joel Jean-Mairet, Ph.D.Director
  • Casper BreumDirector
Offering amount
$17M
Amount sold
$10M
First sale
Jun 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedApr 2019 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Raj Parekh, Ph.D.Director
  • Casper BreumDirector
  • Art PappasDirector
  • Julie FederExecutive Officer
  • Lewis GeffenExecutive Officer
  • Giovanni Mariggi, Ph.D.Director
  • Joel Jean-Mairet, Ph.D.Director
  • Elisabet de los Pinos, Ph.D.Executive Officer, Director
  • Alan E. Walts, Ph.D.Director
  • Mark ChinDirector
Offering amount
$40M
Amount sold
$20M
First sale
Apr 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42.3MraisedDec 2018 · 42 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lewis GeffenExecutive Officer
  • Casper BreumDirector
  • Julie FederExecutive Officer
  • Dale Pfost, Ph.D.Director
  • Mark ChinDirector
  • Art PappasDirector
  • Elisabet de los Pinos, Ph.D.Executive Officer, Director
  • Joel Jean-Mairet, Ph.D.Director
  • Alan E. Walts, Ph.D.Director
Offering amount
$42.5M
Amount sold
$42.3M
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.5MraisedNov 2017 · 38 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Raj Parekh, Ph.D.Director
  • Michael WyzgaExecutive Officer
  • Joel Jean-Mairet, Ph.D.Director
  • Jose' Baselga, Ph.D.Director
  • Dale Pfost, Ph.D.Director
  • Alan E. Walts, Ph.D.Director
  • Elisabet de los Pinos, Ph.D.Executive Officer, Director
  • Lewis GeffenExecutive Officer
  • Peter WirthDirector
  • Art PappasDirector
Offering amount
$11.5M
Amount sold
$11.5M
First sale
Sep 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21MraisedMar 2015 · 21 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Peter B. FinnExecutive Officer
  • Alan Walts, Ph.D.Director
  • Elisabet de los Pinos, Ph.D.Executive Officer, Director
  • Peter WirthDirector
  • Javier GarciaDirector
  • Joel Jean-Mairet, Ph.D.Director
  • Art PappasDirector
  • Jose Baselga, Ph.D.Director
  • Dale Pfost, Ph.D.Director
Offering amount
$34.5M
Amount sold
$21M
Minimum investment
$25K
Proceeds to insiders
$1.2M
First sale
Feb 2015
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$4MraisedAug 2014 · 41 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Israel RuizDirector
  • Peter B. FinnExecutive Officer
  • Jose Baselga, Ph.d.Director
  • Peter WirthDirector
  • Alan WaltsDirector
  • Elisabet de los Pinos, Ph.d.Executive Officer, Director
  • Javier GarciaDirector
Offering amount
$4M
Amount sold
$4M
Minimum investment
$25K
Proceeds to insiders
$500K
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2009
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1.3MraisedJan 2014 · 16 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Jose Baselga, Ph.d.Director
  • Israel RuizDirector
  • Alan WaltsDirector
  • Salvador Garcia-AtanceDirector
  • Elisabet de los Pinos, Ph.d.Executive Officer, Director
  • Peter B. FinnExecutive Officer
  • Peter WirthDirector
Offering amount
$1.3M
Amount sold
$1.3M
Minimum investment
$25K
Proceeds to insiders
$400.5K
First sale
Aug 2013
Incorporated
Corporation, Delaware, 2009
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Aro Biotherapeutics28 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Doximity25 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Practo22 shared keywordsPracto is a healthcare platform offering online video consultations with verified doctors across specialties and appointment booking for in-clinic visits. It serves patients in India, connecting them with doctors across areas such as dentistry, gynecology, pediatrics, and general medicine.

Companies competing with Aura Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Aura Biosciences (NASDAQ:AURA) Shares Up 6.5% – Here’s What Happened - Ticker Reporttickerreport.com · Aug 2026Adage Capital reports 8.44% stake in Aura Biosciences | AURA SEC Filing - Form SCHEDULE 13G/Astocktitan.net · Aug 2026Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval (AURA) | Seeking Alphaseekingalpha.com · Aug 2026Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summarytradingview.com · Aug 2026Aura Biosciences (NASDAQ: AURA) boosts cash runway with $280.8M raise and buybackstocktitan.net · May 2026

Frequently asked questions

What does Aura Biosciences do?
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.
Who founded Aura Biosciences?
Aura Biosciences was founded by Elisabet de los Pinos, Ph.D., Elisabet de los Pinos in 2009.
Who are Aura Biosciences's investors?
Aura Biosciences's investors include Advent Life Sciences, Chiesi Ventures, Droia Ventures, Foresite Capital, Jazzya Investments, Medicxi, Myelin VC, OrbiMed and 3 more.
How much funding has Aura Biosciences raised?
Aura Biosciences has disclosed $190.6M raised across 8 of its 9 known rounds.
Where is Aura Biosciences headquartered?
Aura Biosciences is headquartered in Cambridge, US.